{
    "id": 12466,
    "fullName": "PRKAA1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PRKAA1 dec exp indicates decreased expression of the Prkaa1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5562,
        "geneSymbol": "PRKAA1",
        "terms": [
            "PRKAA1",
            "AMPK",
            "AMPKa1"
        ]
    },
    "variant": "dec exp",
    "createDate": "09/28/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7266,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock-down of PRKAA1 with siRNA resulted in decreased response to Glucophage (metformin) induced growth inhibition in lymphoma cell lines in culture (PMID: 22378068).",
            "molecularProfile": {
                "id": 12614,
                "profileName": "PRKAA1 dec exp"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3007,
                    "pubMedId": 22378068,
                    "title": "Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22378068"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7267,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock-down of PRKAA1 with siRNA reduced the additive effect of Glucophage (metformin) and Torisel (temsirolimus) combination treatment in lymphoma cell lines in culture (PMID: 22378068).",
            "molecularProfile": {
                "id": 12614,
                "profileName": "PRKAA1 dec exp"
            },
            "therapy": {
                "id": 1325,
                "therapyName": "Metformin + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3007,
                    "pubMedId": 22378068,
                    "title": "Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22378068"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 12614,
            "profileName": "PRKAA1 dec exp",
            "profileTreatmentApproaches": [
                {
                    "id": 6908,
                    "name": "Metformin",
                    "profileName": "PRKAA1 dec exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}